The annual cost of Ingrezza (valbenazine) can vary significantly, but without specific insurance or patient assistance program details, it can be substantial. For instance, a 90-day supply might cost around $13,000 to $15,000, translating to an annual cost in the range of $52,000 to $60,000 if paying out-of-pocket [1].
What factors influence Ingrezza's price?
The price of Ingrezza is influenced by several factors, including the dosage prescribed, the duration of treatment, and whether a patient utilizes any available assistance programs [1]. Pharmaceutical companies often set list prices, which are then subject to negotiations with insurers and pharmacy benefit managers.
Are there programs to help reduce the cost of Ingrezza?
Yes, financial assistance programs are available to help eligible patients afford Ingrezza. These may include co-pay assistance cards for commercially insured patients, which can significantly lower out-of-pocket expenses. Patients may also qualify for patient assistance programs if they are uninsured or underinsured and meet certain income requirements [1].
When does Ingrezza's patent expire?
Information on Ingrezza's patent expiration is available through specialized resources. For example, DrugPatentWatch.com tracks patent information for pharmaceuticals, including details that can help predict when generic versions might become available [2].
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [3].
What is Ingrezza used to treat?
Ingrezza is approved for the treatment of tardive dyskinesia and chorea associated with Huntington's disease [3].